No Data
No Data
Trevena Announces $2M Financing and Reduction in Liabilities
Trevena Announces Amendment To Ex-US Royalty Financing With R-Bridge Healthcare Fund; Expects $2M Payment And Potential Additional $8M Based On OLINVYK US Milestones; Liability Reduced By $10M
Trevena Announces Amendment To Ex-US Royalty Financing With R-Bridge Healthcare Fund; Expects $2M Payment And Potential Additional $8M Based On OLINVYK US Milestones; Liability Reduced By $10M
Express News | Trevena Inc: Expects a $10 Mln Reduction in Liabilities Associated With Its Ex-US Royalty Financing
Express News | Trevena Inc - to Receive $8 Million in Future Potential Tranches
Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection With Existing Ex-US Royalty Financing
Trevena, Inc. (Nasdaq: TRVN) today announced an amendment (the "Amendment") to its March 2022 ex-US royalty-based financing (the "Royalty Financing") with R-Bridge Healthcare Fund, L.P. (R-Bridge).
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in today's pre-market trading after the company announced expanded US FDA approval of ELEVIDYS to Duchenne Muscular Dystrophy patients a